Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to verify whether there were differences in health-related quality of life of patients with allergic rhinitis treated with bilastine 20 mg compared to those treated with loratadine 10 mg.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidade do Sul de Santa Catarina
• Treatments: Loratadine

Criteria

Inclusion Criteria:

• clinical diagnosis of allergic rhinitis (a typical history of rhinitis symptoms:

coryza, sneezing, nasal obstruction, nasal itching, and eye symptoms, and hypersensitivity tests for specific IgE measured by Radioallergosorbent Test (RAST) or skin tests

• patients classified as with intermittent rhinitis (symptoms during less than 4 days per week) or persistent rhinitis (symptoms during more than 4 days per week) of moderate to severe intensity (annoyance impairing the quality and quantity of sleep and interfering with daily activities)

Exclusion Criteria:

• pregnancy or breast-feeding;

• non-allergic rhinitis (vasomotor, infectious or drug-induced);

• known hypersensitivity to antihistamines;

• clinical disorders that might affect the assessment;

• nasal diseases that could lead to complete blockage or one of the nostrils blockage, such as tumors or septal deviation;

• therapy with immunotherapy;

• use of antihistamines or disodium cromoglycate within the past four weeks;

• use of topical or systemic corticosteroids, immunosuppressants or any investigational drug within the last two weeks;

• use of topical antihistamines or nasal decongestants within the last 48 hours;

• use of deposit steroid within the last month.